Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 03, 2023

BUY
$0.32 - $15.2 $3,200 - $152,000
10,000 Added 200.0%
15,000 $4,000
Q2 2022

Jul 12, 2022

BUY
$0.62 - $1.94 $2,170 - $6,790
3,500 Added 233.33%
5,000 $4,000
Q4 2020

Feb 03, 2021

BUY
$4.92 - $30.67 $7,380 - $46,005
1,500 New
1,500 $7,000

Others Institutions Holding APRE

About Aprea Therapeutics, Inc.


  • Ticker APRE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Description
  • Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...
More about APRE
Track This Portfolio

Track Sugarloaf Wealth Management, LLC Portfolio

Follow Sugarloaf Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sugarloaf Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sugarloaf Wealth Management, LLC with notifications on news.